questions pertinent to the scope of the guideline and a set of outcome measures of importance to patients, ranked according to the GRADE methodology (see section 3.0).
A systematic literature search of PubMed, MEDLINE, EMBASE, Cochrane and AMED databases was conducted by the technical team to identify key articles for hidradenitis suppurativa up to July 2018; search terms and strategies are detailed in the supplementary information (Appendix K). Additional references relevant to the topic were also isolated from citations in reviewed literature. Data extraction and critical appraisal were carried out by two clinicians and checked by the technical team. Data synthesis, evidence summaries, lists of excluded studies and the PRISMA diagram were prepared by the technical team. Evidence from included studies was rated according to the GRADE system (high, moderate, low or very low quality). Recommendations are based on evidence drawn from systematic reviews of the literature pertaining to the clinical questions identified, following discussions with the entire GDG and factoring in all four factors that would affect its strength rating according to the GRADE approach (i.e. balance between desirable and desirable effects, quality of evidence, patient values and preferences and resource allocation). All GDG members contributed towards drafting and/or reviewing the narratives and information in the guideline and supporting information documents. When there is insufficient evidence from the literature, informal consensus is reached based on the experience of the GDG. The summary of findings with forest plots (Appendix D), GRADE evidence profiles indicating the quality of evidence (Appendix E), clinical evidence summary (Appendix B), summary of included comparative studies (Appendix F), narrative findings tables for non-comparative studies (Appendix G), tables Linking the Evidence To the Recommendations (LETR, Appendix C), PRISMA flow diagram (Appendix H) and lists of excluded studies (Appendix I) are detailed in the supporting information. The strength of recommendation is expressed by the wording and symbols as shown in Table 1 .
Strength

Wording Symbols Definition
Strong recommendation for the use of an intervention "Offer" (or similar, e.g. "Use", "Provide", "Take", "Investigate", etc.)

Benefits of the intervention outweigh the risks; most patients would choose the intervention whilst only a small proportion would not; for clinicians, most of their patients would receive the intervention; for policy makers, it would be a useful performance indicator.
Weak recommendation for the use of an intervention "Consider"  Risks and benefits of the intervention are finely balanced; most patients would choose the intervention, but many would not; clinicians would need to consider the pros and cons for the patient in the context of the evidence; for policy makers, it would be a poor performance indicator where variability in practice is expected.
No recommendation Θ
Insufficient evidence to support any recommendation.
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INTRODUCTION
There is currently a paucity of effective treatment options for HS, but common medical therapy approaches include antiseptic washes, steroid injections, topical and oral antibiotics (single agents or combination treatment), retinoids, dapsone, oral contraceptive agents, oral immunomodulators, and anti-TNF therapy. Surgical procedures range from incision and drainage for acute flares, narrow margin excision and extensive excision with closure by secondary intention, skin flap or graft. Other treatment options include radiotherapy, psoralen and UVA (PUVA) phototherapy, photodynamic therapy and laser therapy.
Clinical questions and outcomes
Management strategies in HS are highly variable and are currently undertaken by both generalists and specialists spanning emergency medicine, internal medicine, dermatology, plastic surgery, urology, gynaecology and general surgery. To address these matters the GDG established several clinical questions pertinent to the scope of the guideline.
In people with hidradenitis suppurativa: 1. What is the efficacy and safety of medical interventions?  topical  conventional systemic  biologic  laser and light  other therapies 2. What is the efficacy and safety of surgical interventions? 3. What are the self-management options and the evidence to support them?
The GDG also established two sets of outcome measures of importance to patients (see Table 2 ), one for medical interventions and another for surgery; these were ranked according to the GRADE methodology 4 by patient/carer representatives, data on which are extracted from included studies (see Appendix F). Outcomes ranked 7, 8 and 9 are critical for decision-making; those ranked 4, 5 and 6 are important but not critical for decision making:
Medical interventions Surgical interventions
Quality 
SUMMARY OF RECOMMENDATIONS
The following recommendations and ratings were agreed upon unanimously by the core members of the GDG and patient/carer representatives. For further information on the wording used for recommendations and strength of recommendation ratings see Table 1 .
The evidence for recommendations is based on the studies as listed. GDG recommendations relating to referral pathways are based on discussion and clinical experience, as evidence-based details are not available at the time of writing. The GDG is aware of the lack of high-quality evidence for some of these recommendations, therefore strong recommendations with an asterisk (*) are based on available evidence, as well as consensus and specialist experience. Good practice point (GPP) recommendations are derived from informal consensus. 
R1 (GPP)
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ALGORITHM
The recommendations and discussions in the LETR (see Appendix C in the supplementary information) and consensus specialist experience were used to produce the management pathway for people with HS ( Figure 1) . 
BACKGROUND 6.1 Definition
Hidradenitis suppurativa (HS) is defined as a "chronic, inflammatory, recurrent, debilitating, skin follicular disease that usually presents after puberty with painful deep seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly, the axillary, inguinal and anogenital regions". 5,6
Epidemiology
Prevalence has been estimated at approximately 1-4% in the U.K. population 7 and the typical age of onset is in the second to fourth decades of life. [8] [9] [10] There is a female predominance (3:1, F:M) and an association with obesity and smoking, with odds ratios of 3.3 and 3.6, respectively, compared with controls. 7 However, non-smoking patients of normal BMI are seen in clinical practice. A population-based study from the USA found that HS prevalence among African American and biracial individuals was 3-fold and 2-fold greater, respectively, than the prevalence in white individuals. 11 There is a nearly doubled risk of cardiovascular-associated death in HS patients compared with controls, 12 in keeping with high rates of smoking and also associations with type 2 diabetes, hyperlipidaemia and hypertension. 7 HS is associated with pilonidal sinus, which may be a phenotypic variant, as well as acne vulgaris 7 People with HS have a higher risk of depression 7, 13 and completed suicide 14 which may relate to HS being a chronic, painful disease with a large impact on quality of life. There is an association between HS and Crohn's disease but not with ulcerative colitis. 7,15
Clinical presentation
HS may present with comedones (characteristically paired), papules, pustules, nodules, cysts, abscesses, sinus tracts and fistulae in flexural areas however there is significant phenotypic variation amongst patients. 16 The condition can cause severe pain, as well as pruritus, chronic discharge (serous, purulent or blood-stained) and a persistent malodour. Longstanding disease can result in fibrosis, dermal contractures, scarring and a consequent reduction in mobility. The disease targets flexural areas, notably the axillae, groin, perineum, buttocks, medial thighs, sub-mammary region, abdominal fold and posterior auricular region. Disease complications include fistula formation (affecting the urethra, bladder or rectum), lymphoedema, anaemia and the development of squamous cell carcinoma (SCC). 17 The associated pain, chronic purulent discharge, persistent malodour and the involvement of intimate sites in HS can result in significant patient morbidity. A survey of 114 patients referred to secondary care revealed an average Dermatology Life Quality Index (DLQI) score of 8.9, 18 demonstrating a moderate effect on quality of life. HS can have far reaching social and economic consequences, affecting sexual health, 19 relationships and employment.
Diagnostic criteria and measures of disease severity
Consensus diagnostic criteria state that individuals require typical lesions (painful nodules, abscesses, sinus tracts, bridged scars or open comedones) in typical sites (axillae, groin, perineal region, perianal region, infra and inter mammary folds or buttocks) and that the disease must be chronic and recurrent. 20 Baseline disease severity in each skin region is often measured using the Hurley staging system (Table 3) . 21 22 or Skindex. 23 Several physician-reported instruments are available in the literature including Sartorius score; 24 however, most have not undergone robust validation. 25 More recently, HiSCR has been developed as an endpoint for clinical trials, defined as a 50% reduction from baseline in inflammatory nodules and abscesses, with no increase in abscesses or draining sinuses. 26 In approving adalimumab for moderate-to-severe HS, NICE used a modified version of the HiSCR endpoint, stipulating that a 25% reduction in inflammatory nodules and abscesses is required to continue therapy. 27 
Stage
Dermatopathology
HS is a clinical diagnosis and histopathological confirmation is rarely needed. Common histopathological features include follicular hyperkeratosis, follicular hyperplasia and follicular occlusion with an associated spongiform infundibulofolliculitis. 28 These changes may be associated with follicular dilatation, follicular rupture and the formation of keratin containing cysts (lined by stratified squamous epithelium), abscesses, sinus tracts, granulomas, fibrosis and scarring.
Disease pathogenesis
The pathogenesis of HS remains poorly understood. Histopathological studies suggest that HS is primarily a disease of follicular occlusion. 28 Up to 42% of HS patients report a family history of the condition and it can follow autosomal dominant inheritance in some kindreds. 29, 30 Recent genetic studies revealed that heterozygous mutations in the gammasecretase genes NCTSN, PSEN1 and PSENEN underlie a few familial cases of HS. 31, 32 These would appear to tie in with the above histopathological studies in so far as alterations in gamma-secretase gene expression in animal models can result in follicular occlusion. 33 The significant inflammatory response seen in HS has led some to speculate that it may be a disease of aberrant immunity and it is noteworthy that immunomodulatory treatments including anti-TNF agents can be of benefit. 34 The female predominance, post-pubertal onset, pre-menstrual flares and clinical improvement often observed during pregnancy imply a role for hormones in HS however the mechanism remains unknown. 35 The role of bacteria in exacerbations is uncertain, for example short courses of antibiotics do not seem to alter natural history of a flare. 10 Antibiotics may confer a benefit via their anti-inflammatory properties rather than any bactericidal or bacteriostatic effects. Obesity may have an impact on HS by mechanically increasing friction at flexural sites (thus potentially damaging follicular outlets), increasing sweat retention or increasing the circulating level of proinflammatory cytokines (for example, IL-1β and TNF-α are both secreted by macrophages within visceral fat). 36, 37 The exact mechanisms by which smoking contributes to disease pathogenesis remain unclear however nicotine has been shown to induce epidermal hyperplasia and follicular plugging. 38
SELF-MANAGEMENT
What can a person with HS do to help manage their condition? In most areas, evidence is weak or absent, however, a list of suggestions is provided below following feedback from patient/carer representatives on the GDG:  Obtain up-to-date information about HS from the BAD's Patient Information Leaflet web page (www.bad.org.uk/leaflets).  Consider joining a patient support group, such as the HS Trust in the U.K.
(www.hstrust.org). Mutual support is available via associated social media groups.  Obtain adequate pain relief from your General Practitioner (GP) to help manage the pain associated with HS flares or chronically active disease.  Avoid tight clothing and synthetic materials that can increase friction and may contribute to flares.  Obtain wound dressings from your GP to help manage actively pus-producing lesions. Incontinence pads might be needed for high volume of discharge.  HS is not a disease of poor hygiene, however, using an antiseptic wash, such as chlorhexidine solution for the shower, available via the GP, may be beneficial.  There is no high-quality evidence that particular diets are helpful in HS.  If you are overweight, weight reduction may improve your disease severity and, depending on BMI, support from NHS weight-management services may be obtained.  Smoking is a risk factor for development of HS and people with HS have a relatively high risk of cardiovascular disease so stopping smoking, if you currently smoke, is an important part of self-management.  Depression is more common in those with HS and it is important to seek help from your GP for low mood, if relevant.
RECOMMENDED AUDIT POINTS
1. In the last 20 consecutive patients diagnosed with hidradenitis suppurativa is there evidence of: a) provision of a patient information leaflet b) an offer of smoking cessation referral, where relevant c) an offer of weight management referral, where relevant
